AstraZeneca Reports P-III Trial (FLAURA2) Results of Tagrisso (osimertinib) for the Treatment of EGFR-Mutated Advanced Lung Cancer
- The P-III trial evaluating Tagrisso (80mg, qd) + CT (pemetrexed (500mg/m2) & cisplatin (75mg/m2) or carboplatin (AUC5)) vs Tagrisso alone in 586 patients with LA (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC across 150+ centres in 20+ countries, incl. in the US, EU, South America & Asia
- The results showed an improvement in PFS over Tagrisso alone. The safety results & discontinuation rates due to AEs were consistent with the established profiles of each therapy, OS data were immature & will be formally assessed at a subsequent analysis
- The data will be shared with global health authorities. Tagrisso is also being studied in the P-III trial (LAURA) for unresectable NSCLC & results are expected in 2023
Ref: Astrazeneca | Image: Astrazenneca
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.